The necessity to adhere to evidence-based indications for hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with ovarian cancer

Hyperthermic intraperitoneal chemotherapy (HIPEC) is a polarizing topic. The efficacy and safety of HIPEC (cisplatin 100 mg/m2 at 40°C for 90 min) after optimal interval cytoreductive surgery (<1 cm residual disease) for stage 3 epithelial ovarian cancer was demonstrated in the OVHIPEC-1